Italia markets open in 6 hours 58 minutes

Corcept Therapeutics Incorporated (0I3Q.L)

LSE - LSE Prezzo differito. Valuta in USD.
Aggiungi a watchlist
24,01+1,32 (+5,84%)
Alla chiusura: 06:13PM BST
Schermo intero
Chiusura precedente22,69
Aperto0,00
Denaro0,00 x 0
Lettera0,00 x 0
Min-Max giorno0,00 - 0,00
Intervallo di 52 settimane
Volume100
Media Volume2.318
Capitalizzazione23,947M
Beta (5 anni mensile)0,48
Rapporto PE (ttm)0,26
EPS (ttm)0,91
Prossima data utili01 mag 2024 - 06 mag 2024
Rendimento e dividendo (futuro)N/D (N/D)
Data ex dividendoN/D
Stima target 1AN/D
  • GlobeNewswire

    Corcept Therapeutics Announces Second Quarter Financial Results and Provides Corporate Update

    MENLO PARK, Calif., Aug. 02, 2023 (GLOBE NEWSWIRE) -- Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrine, oncology, metabolism and neurology disorders by modulating the effects of the hormone cortisol, today reported results for the quarter ended June 30, 2023. Financial Results Revenue of $117.7 million, a 14 percent increase from second quarter 2022Increase in 2023 revenue guidance to $4

  • GlobeNewswire

    Corcept Therapeutics to Announce Second Quarter Financial Results, Provide Corporate Update and Host Conference Call

    MENLO PARK, Calif., July 26, 2023 (GLOBE NEWSWIRE) -- Corcept Therapeutics Incorporated (NASDAQ: CORT) today announced it will report second quarter financial results and provide a corporate update on August 2, 2023. The company will also host a conference call that day at 5:00 p.m. Eastern Time (2:00 p.m. Pacific Time). Conference Call Information Participants must register in advance of the conference call by clicking here. Upon registering, each participant will receive a dial-in number, and

  • GlobeNewswire

    Corcept’s Miricorilant Shows Great Promise in Treatment of Non-Alcoholic Steatohepatitis (NASH)

    Phase 1b study demonstrates that miricorilant, a selective cortisol modulator, effectively reduces liver fat, improves liver health and key metabolic and lipid measures and is well-toleratedCorcept will initiate a Phase 2b study in the fourth quarter MENLO PARK, Calif., July 17, 2023 (GLOBE NEWSWIRE) -- Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrine, oncology, metabolism and neurology